Ronocyte - Instructions For Use, Price, Reviews, Injections 1000 Mg

Table of contents:

Ronocyte - Instructions For Use, Price, Reviews, Injections 1000 Mg
Ronocyte - Instructions For Use, Price, Reviews, Injections 1000 Mg

Video: Ronocyte - Instructions For Use, Price, Reviews, Injections 1000 Mg

Video: Ronocyte - Instructions For Use, Price, Reviews, Injections 1000 Mg
Video: How to give a Caverject injection 2023, April


Ronocyte: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  10. 10. Use in childhood
  11. 11. Use in the elderly
  12. 12. Drug interactions
  13. 13. Analogs
  14. 14. Terms and conditions of storage
  15. 15. Terms of dispensing from pharmacies
  16. 16. Reviews
  17. 17. Price in pharmacies

Latin name: Ronocit

ATX code: N06BX06

Active ingredient: citicoline (Citicoline)

Manufacturer: С. К. Rompharm Company S. R. L. (SC Rompharm Company, SRL) (Romania)

Description and photo update: 2019-14-12

Solution for intravenous and intramuscular injection Ronocyte
Solution for intravenous and intramuscular injection Ronocyte

Ronocyte is a nootropic drug with a broad spectrum of action.

Release form and composition

The drug is produced in the form of a solution for intravenous (i / v) and intramuscular (i / m) administration: colorless or light yellow transparent liquid (4 ml each in colorless glass ampoules, 5 ampoules in blisters, in a cardboard box 1 packaging and instructions for use of Ronocyte).

1 ampoule (4 ml) contains:

  • active substance: citicoline sodium - 522.52 mg or 1045.04 mg, which is equivalent to 500 mg or 1000 mg of citicoline, respectively;
  • auxiliary components: 1M hydrochloric acid solution or 1M sodium hydroxide solution, water for injection.

Pharmacological properties


Ronocyte is a nootropic drug with a wide spectrum of pharmacological action.

Its active substance, citicoline, is a precursor of key ultrastructural components of the cell membrane, mainly phospholipids. The mechanism of action of the drug is due to the ability of citicoline, to prevent excessive formation of free radicals, to potentiate the restoration of damaged cell membranes, to inhibit the action of phospholipases, acting on the mechanisms of apoptosis to prevent cell death.

The use of the drug in the acute period of stroke improves cholinergic transmission, reduces the amount of damaged brain tissue.

In traumatic brain injury, it helps to reduce the period of post-traumatic coma, reduce the severity of neurological symptoms and the duration of the recovery course.

In patients with chronic hypoxia of the brain, the clinical effect of citicoline is observed in the treatment of cognitive disorders, including emotional lability, memory impairment, lack of initiative, difficulty in self-care or performing routine activities.

The effectiveness of the drug in the treatment of motor and sensory neurological disorders of degenerative and vascular genesis has been confirmed.


After parenteral (intravenous or intramuscular) administration of Ronocyte, citicoline is well absorbed, this contributes to a significant increase in the concentration of choline in the blood plasma.

Citicoline largely enters the brain and is distributed in its structures. It forms part of the fraction of structural phospholipids after active incorporation into cytoplasmic, cellular and mitochondrial membranes.

There are no data on the excretion of citicoline in breast milk.

It is metabolized in the liver to form choline and cytidine. Choline fractions are rapidly incorporated into structural phospholipids and cytidine fractions.

Only 15% of the administered dose of citicoline is excreted from the body (12% - with exhaled air and less than 3% - through the kidneys). The rate of excretion of the active substance decreases rapidly: with exhaled air during the first 15 hours, through the kidneys - during the first 36 hours; then its decline occurs much more slowly.

Indications for use

  • acute period of ischemic stroke and traumatic brain injury - as part of complex therapy;
  • recovery period after ischemic or hemorrhagic stroke, traumatic brain injury;
  • degenerative and vascular diseases of the brain, accompanied by cognitive and behavioral impairments.



  • severe vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);
  • simultaneous use of medicines containing meclofenoxate;
  • breast-feeding;
  • age up to 18 years;
  • individual intolerance to the components of the drug.

With caution, only in cases where the expected benefit to the mother outweighs the potential risk to the fetus, it is allowed to prescribe the drug during pregnancy.

Ronocyte, instructions for use: method and dosage

Ronocyte solution is used by i / v (preferably) or i / m administration.

The intravenous drug can be administered by jet (duration of intravenous injection is 5 minutes) or by drip (infusion rate is 40-60 drops per minute).

With the intramuscular injection of Ronocyte, it should not be allowed to be injected again in the same place.

After opening the ampoule, the solution should be used immediately, the rest should be disposed of.

When preparing for infusion, the drug can be dissolved in all types of intravenous isotonic solutions and dextrose (glucose) solutions.

Recommended daily dosage:

  • acute period of ischemic stroke and traumatic brain injury: from the moment of diagnosis - 2000 mg, divided into 2 injections with equal intervals between procedures. The duration of the course is at least 42 days. After 3-5 days of parenteral administration of citicoline, patients with normal swallowing function can be transferred to treatment with oral dosage forms;
  • recovery period after traumatic brain injury, ischemic or hemorrhagic stroke, cognitive impairment: from 500 to 2000 mg, depending on the severity of the symptoms of the disease. The doctor prescribes the duration of the course of therapy individually. If necessary, treatment with oral citicoline is possible.

In the absence of confidence that intracranial bleeding has stopped, the daily dose of Ronocyte 1000 mg should not be exceeded, the rate of intravenous infusion should not exceed 30 drops per minute.

Elderly patients do not need dose adjustment.

Side effects

  • from the nervous system: very rarely - headache, dizziness, unwanted reactions from the parasympathetic system, numbness in the paralyzed limbs, tremor;
  • mental disorders: very rarely - insomnia, agitation, hallucinations;
  • from the side of the vessels: very rarely - arterial hypertension, arterial hypotension;
  • from the respiratory system, chest and mediastinal organs: very rarely - shortness of breath;
  • from the gastrointestinal tract: very rarely - decreased appetite, diarrhea, nausea, vomiting;
  • on the part of the hepatobiliary system: very rarely - a violation of the activity of hepatic enzymes;
  • on the part of the skin and subcutaneous tissues: very rarely - rash, pruritus, hyperemia, purpura, urticaria, anaphylactic shock;
  • general disorders: very rarely - chills;
  • violations at the injection site: very rarely - a feeling of heat, edema.


Overdose symptoms have not been established.

special instructions

Any undesirable effects associated with the use of the drug must be reported to the attending physician.

Patients with brain injuries should be prescribed medications such as mannitol and corticosteroids to reduce intracranial pressure simultaneously with Ronocyte.

Influence on the ability to drive vehicles and complex mechanisms

During the period of treatment with Ronocyte, patients need to be careful when driving and working with complex mechanisms.

Application during pregnancy and lactation

During pregnancy, citicoline may be prescribed only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

The use of Ronocyte during breastfeeding is contraindicated. If it is necessary to use citicoline during lactation, breastfeeding should be discontinued.

Pediatric use

There are no clinical data on the use of the drug in children, therefore, the administration of Ronocyte injections to patients under the age of 18 is contraindicated.

Use in the elderly

Elderly patients do not need dose adjustment.

Drug interactions

It should be borne in mind that Ronocyte enhances the effects of levodopa.

Citicoline should not be used with concomitant therapy with drugs containing meclofenoxate.

The simultaneous use of Ronocyte with hemostatic drugs, intracranial antihypertensive agents and perfusion fluids is allowed.


Ronocyte analogs are Citicoline, Quinel, Lexuver, Neipilept, Neuropol, Neurocholine, Nootsil, Proneiro, Recognan, Ceraxon, Ceralin-Lekpharm, Ceresil Canon, Encetron-SOLOpharm.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Ronocyte

There are no reviews of patients or specialists about Ronocyte.

Ronocyte price in pharmacies

The price for Ronocyte 1000 mg / 4 ml and 500 mg / 4 ml has not been established due to the lack of the drug in the pharmacy network.

Maria Kulkes
Maria Kulkes

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic